Meda pays $95m for Jazz women's products
This article was originally published in Scrip
Executive Summary
Jazz Pharmaceuticals has completed the sales of its women's health business to Meda of Sweden for $95 million in cash. The six products being transferred generated sales of $30.4 million in 2011, and include the estradiol gel product Elestrin.